Skip to main content
Lotties
1 - src: /sites/elevidyshcp/files/2024-08/ELE-HCP-2.0-Crecent-7-001.json / styles: top: -290px;left: -280px;width: 592px;height: 751px; / flip x: 0
2 - src: /sites/elevidyshcp/files/2024-08/ELE-HCP-1.0-2.0-Crecent-8-001_0.json / styles: top: 890px;right: -390px;width: 610px;height: 1841px;transform: scaleX(-1); / flip x: 1

Evaluated in a robust clinical trial program in Duchenne1

ELEVIDYS was evaluated in multiple clinical trials that included a broad patient population of more than 200 ambulatory (n=206) and non-ambulatory (n=8) individuals. Clinical trials are ongoing to verify long-term data as well as outcomes in non-ambulatory individuals.22-24

KEY DEMOGRAPHICS1

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 1 (Part 1)

ELEVIDYS

n=20

Placebo

n=21

65%

81%

6.3

(4.5 to 7.9)

6.2

(4.3 to 7.9)

23.3

(18.0 to 34.5)

21.6

(15.0 to 30.0)

STUDY 2*

ELEVIDYS

N=48

77%

7.7

(3.2 to 20.2)

30.1

(12.5 to 80.1)

STUDY 3

ELEVIDYS

n=63

Placebo

n=62

78%

74%

6.0

(4.1 to 7.9)

6.1

(4.0 to 7.9)

21.3

(13.5 to 38.5)

22.4

(14.4 to 41.6)

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 1 (Part 1)

ELEVIDYS

n=20

Placebo

n=21

65%

81%

6.3

(4.5 to 7.9)

6.2

(4.3 to 7.9)

23.3

(18.0 to 34.5)

21.6

(15.0 to 30.0)

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 2*

ELEVIDYS

N=48

77%

7.7

(3.2 to 20.2)

30.1

(12.5 to 80.1)

 

Characteristic
Race group, White (%)
Mean age, years (range)
Mean weight, kg (range)

STUDY 3

ELEVIDYS

n=63

Placebo

n=62

78%

74%

6.0

(4.1 to 7.9)

6.1

(4.0 to 7.9)

21.3

(13.5 to 38.5)

22.4

(14.4 to 41.6)

* Cohorts 1, 2, 4, and 5a included 40 ambulatory patients; Cohorts 3 and 5b included 8 non-ambulatory patients.
Patients with moderate to severe left ventricular ejection fracture (LVEF) impairment have not been studied in clinical trials with ELEVIDYS.

see clinical trial results
Study 1

Completed, multicenter trial in 41 ambulatory males aged 4 to 7 years1:

  • Part 1: 48-week, double-blind, placebo-controlled randomized period; randomization stratified by age (4 to 5 years vs 6 to 7 years)
  • Part 2: 48-week, double-blind, placebo-controlled crossover† period after Part 1
PRIMARY OBJECTIVES
  • ELEVIDYS micro-dystrophin expression in skeletal muscle, as measured by western blot
  • Motor function, as measured by NSAA total score
KEY BASELINE CHARACTERISTICS (PART 1)
Characteristic

All

N=41

ELEVIDYS

n=20

Placebo

n=21

Mean age, years (range)

6.3

(4.3 to 7.9)

6.3

(4.5 to 7.9)

6.2

(4.3 to 7.9)

Mean weight, kg (range)

22.4

(15.0 to 34.5)

23.3

(18.0 to 34.5)

21.6

(15.0 to 30.0)

Mean NSAA total score (range)

21.2

(13 to 29)

19.8

(13 to 26)

22.6

(15 to 29)

Mean time to rise from floor, seconds (range)

4.3

(2.7 to 10.4)

5.1

(3.2 to 10.4)

3.6

(2.7 to 4.8)

† In the crossover period, patients randomized to placebo in Part 1 received ELEVIDYS in Part 2, and patients randomized to ELEVIDYS in Part 1 received placebo in Part 2.

NSAA=North Star Ambulatory Assessment; TTR=time to rise.

Study 2

Ongoing, open-label, multicenter trial in 40 ambulatory males (cohorts 1, 2, 4, and 5a) and 8 non-ambulatory males (cohorts 3 and 5b)1

PRIMARY OBJECTIVE
  • ELEVIDYS micro-dystrophin in skeletal muscles, as measured by western blot
KEY BASELINE CHARACTERISTICS
Characteristic

Cohort 1

n=20

Cohort 2

n=7

Cohort 3

n=6

Cohort 4

n=7

Cohort 5a

n=6

Cohort 5b

n=2

Mean age, years (range)

5.8

(4.4 to 7.9)

10.1

(8.0 to 12.1)

15.3

(9.9 to 20.2)

3.5

(3.2 to 3.9)

6.7

(4.7 to 8.6)

13.4

(12.3 to 14.6)

Mean weight, kg (range)

21.2

(15.2 to 33.1)

37.1

(28.0 to 50.5)

59.9

(36.1 to 80.1)

15.2

(12.5 to 16.5)

32.1

(19.1 to 47.4)

51.2

(43.4 to 59.0)

Mean NSAA total score (range)

22.1

(18 to 26)

20.7

(17 to 26)

NA‡

12.9

(11 to 17)

22.5

(18 to 30)

NA‡

Mean TTR from floor, seconds (range)

4.2

(2.4 to 8.2)

5.9

(3.8 to 9.7)

NA‡

5.2

(3.8 to 6.7)

4.6

(2.5 to 7.7)

NA‡

Characteristic

Cohort 1

n=20

Cohort 2

n=7

Cohort 3

n=6

Mean age, years (range)

5.8

(4.4 to 7.9)

10.1

(8.0 to 12.1)

15.3

(9.9 to 20.2)

Mean weight, kg (range)

21.2

(15.2 to 33.1)

37.1

(28.0 to 50.5)

59.9

(36.1 to 80.1)

Mean NSAA total score (range)

22.1

(18 to 26)

20.7

(17 to 26)

NA‡

Mean TTR from floor, seconds (range)

4.2

(2.4 to 8.2)

5.9

(3.8 to 9.7)

NA‡

Characteristic

Cohort 4

n=7

Cohort 5a

n=6

Cohort 5b

n=2

Mean age, years (range)

3.5

(3.2 to 3.9)

6.7

(4.7 to 8.6)

13.4

(12.3 to 14.6)

Mean weight, kg (range)

15.2

(12.5 to 16.5)

32.1

(19.1 to 47.4)

51.2

(43.4 to 59.0)

Mean NSAA total score (range)

12.9

(11 to 17)

22.5

(18 to 30)

NA‡

Mean TTR from floor, seconds (range)

5.2

(3.8 to 6.7)

4.6

(2.5 to 7.7)

NA‡

‡ Not evaluated in non-ambulatory patients.

NSAA=North Star Ambulatory Assessment; TTR=time to rise.

Study 3

Ongoing, randomized, multicenter, double-blind, placebo-controlled trial in 125 ambulatory males aged 4 to 7 years1

PRIMARY OBJECTIVE
  • Motor function, as measured by NSAA total score
KEY SECONDARY OBJECTIVES
  • ELEVIDYS micro-dystrophin expression in skeletal muscle, as measured by western blot
  • Motor function, as measured by:
    • TTR from floor
    • Time of 10MWR
ADDITIONAL OBJECTIVES
  • Motor function, as measured by:
    • Time of 100MWR
    • Time to ascend 4 steps
KEY BASELINE CHARACTERISTICS1,2,25
Characteristic

ELEVIDYS

n=63

Placebo

n=62

Mean age, years (range)
  4-5 years, n (%)
  6-7 years, n (%)

6.0 (4.1 to 7.9)
30 (47.6)
33 (52.4)

6.1 (4.0 to 7.9)
29 (46.8)
33 (53.2)

Mean weight, kg (range)

21.3 (13.5 to 38.5)

22.4 (14.4 to 41.6)

Mean time since corticosteroid treatment started, years (range)

1.07 (0.23 to 6.17)

0.97 (0.24 to 4.01)

PRIMARY OBJECTIVES
Mean NSAA total score, points (range)

23.10 (14 to 32)

22.82 (15.5 to 30)

KEY SECONDARY OBJECTIVES
Mean TTR from floor, seconds (range)

3.52 (1.9 to 5.8)

3.60 (2.3 to 5)

Mean 10MWR, seconds (range)

4.82 (3.2 to 6.9)

4.92 (3.7 to 7)

ADDITIONAL OBJECTIVES
Mean 100MWR, seconds (range)

60.67 (38.0 to 129.2)

63.01 (38.7 to 118.1)

Mean time to ascend 4 steps, seconds (range)

3.17 (1.6 to 7.1)

3.37 (1.5 to 7.1)

MWR=meter walk/run; NSAA=North Star Ambulatory Assessment; TTR=time to rise.

see clinical trial results

References:

  • 1. ELEVIDYS. Prescribing information. Sarepta Therapeutics, Inc; August 2024.
  • 2. Data on file. Sarepta Therapeutics, Inc. Cambridge, MA.
  • 22. A long-term follow-up study of participants who received delandistrogene moxeparvovec (SRP-9001) in a previous clinical study (EXPEDITION). Clinicaltrials.gov identifier: NCT05967351. Updated October 21, 2024. Accessed October 24, 2024. https://clinicaltrials.gov/study/NCT05967351
  • 23. A gene transfer therapy study to evaluate the safety and efficacy of delandistrogene moxeparvovec (SRP-9001) in non-ambulatory and ambulatory participants with Duchenne muscular dystrophy (DMD) (ENVISION). Clinicaltrials.gov identifier: NCT05881408. Updated October 24, 2024. Accessed October 24, 2024. https://clinicaltrials.gov/study/NCT05881408
  • 24. An observational study comparing delandistrogene moxeparvovec with standard of care in participants with Duchenne muscular dystrophy (ENDURE). Clinicaltrials.gov identifier: NCT06270719. Updated September 3, 2024. Accessed October 18, 2024. https://clinicaltrials.gov/study/NCT06270719
  • 25. Mendell JR, Muntoni F, McDonald CM, et al. AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial. Nat Med. 2024. doi:10.1038/s41591-024-03304-z

Indication

ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age:

  • For patients who are ambulatory and have a confirmed mutation in the DMD gene
  • For patients who are non-ambulatory and have a confirmed mutation in the DMD gene.

The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin (noted hereafter as “micro-dystrophin”) in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

 

Important Safety Information

CONTRAINDICATION:
ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene.

WARNINGS AND PRECAUTIONS:
Infusion-related Reactions:

  • Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate.
  • ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available.
  • Discontinue infusion for anaphylaxis. 

Acute Serious Liver Injury:

  • Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks.
  • Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (eg, acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled.
  • Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels).
  • Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended.

Immune-mediated Myositis:

  • In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed.
  • Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction.
  • Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [eg, calcineurin-inhibitor] in addition to corticosteroids) based on patient’s clinical presentation and medical history if these symptoms occur.

Myocarditis:

  • Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials.
  • If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath.
  • Advise patients to contact a physician immediately if they experience cardiac symptoms.

Preexisting Immunity against AAVrh74:

  • In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies.
  • Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration.
  • ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400.

Adverse Reactions:

  • The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia.

Report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).

Please see full Prescribing Information.

Read More Close